Health & bio
FDA accelerates Kresladi for pediatric LAD-I
FDA granted accelerated approval to Kresladi on March 27 for pediatric severe leukocyte adhesion deficiency (LAD-I).
Primary sources · 1
FDA granted accelerated approval to Kresladi on March 27 for pediatric severe leukocyte adhesion deficiency (LAD-I).
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.